Skyler Stein

Skyler Stein serves as the President (Global) at Gladskin since July 2018, where the mission focuses on enhancing the quality of life for individuals with inflammatory skin conditions using innovative non-prescription products. Previously, Skyler held the position of Head of North America at Clarity Genomics, Inc. from 2016 to 2019, contributing to the development of a platform aimed at advancing healthcare through human microbiome insights. Additional experience includes a brief tenure at Obvious Ventures in 2017, leading sector analyses in the microbiome space, and six years at Bregal Investments as Principal in Private Equity, overseeing significant investment transactions and portfolio management. Early career included roles at Macquarie Group as a Senior Associate and Associate in Private Equity, as well as an Investment Banking Analyst. Skyler holds an MBA from Harvard Business School and a Bachelor’s degree in Energy and Ecological Economics from Duke University.